ADVERTISEMENT
Poster
2757082
Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder
Abstract: Background: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. In real-world settings, OLZ/SAM treatment may be associated with healthcare resource utilization (HCRU) reductions. This study examined the impact of initiating treatment with OLZ/SAM on HCRU among patients with schizophrenia (SZ) or bipolar I disorder (BD-I).
Methods: This retrospective analysis utilized administrative claims data from April 19, 2021, to December 31, 2022, from Komodo Healthcare Map. Adults with SZ or BD-I with continuous enrollment ≥6 months before (baseline) and after (follow-up) OLZ/SAM initiation were eligible. Inpatient (IP) admissions, lengths of stay (LOS), and emergency department (ED) and outpatient (OP) visits were compared between the 6-month baseline and follow-up periods.
Results: Patients (SZ: n=855; BD-I: n=691) had a mean age of ~40 years (female: SZ=47%; BD-I=69%). Proportions of patients with all-cause IP admissions and ED visits significantly decreased (IP: P
Sign Up
Psych Congress Network Newsletter
